BIOMAT Database Logo BIOMAT Database Logo

Vemurafenib in melanoma with BRAF V600E mutation. 2011

Jason P Lott

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D048493 Proto-Oncogene Proteins B-raf A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2. B-raf Kinase,BRAF Kinase,B-raf Kinases,BRAF Kinases,Proto-Oncogene Protein B-raf,B raf Kinase,B raf Kinases,B-raf, Proto-Oncogene Protein,B-raf, Proto-Oncogene Proteins,Kinase, B-raf,Kinase, BRAF,Protein B-raf, Proto-Oncogene,Proteins B-raf, Proto-Oncogene,Proto Oncogene Protein B raf,Proto Oncogene Proteins B raf

Related Publications

Jason P Lott
Vemurafenib in melanoma with BRAF V600E mutation.
October 2011, The New England journal of medicine,
Jason P Lott
Vemurafenib in melanoma with BRAF V600E mutation.
October 2011, The New England journal of medicine,
Jason P Lott
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
June 2011, The New England journal of medicine,
Jason P Lott
Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
July 2012, Clinical therapeutics,
Jason P Lott
Dabrafenib in advanced melanoma with BRAF V600E mutation.
February 2014, The Journal of community and supportive oncology,
Jason P Lott
BRAF V600E Mutation in Involuting Nevus in a Patient Treated With Vemurafenib.
June 2017, JAMA dermatology,
Jason P Lott
BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas.
January 2018, Frontiers in oncology,
Jason P Lott
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
May 2012, Future oncology (London, England),
Jason P Lott
Braf V600E mutation in melanoma: translational current scenario.
September 2016, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
Jason P Lott
A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
February 2018, Lung cancer (Amsterdam, Netherlands),
Copied contents to your clipboard!